BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34761527)

  • 1. Sensitive detection of GATA1 mutations using complementary DNA-based analysis for transient abnormal myelopoiesis associated with the Down syndrome.
    Mizuta S; Yamane N; Mononobe S; Watanabe A; Kitamura R; Takahara T; Matsushima C; Yoshida A; Okamoto S; Tanaka K; Iwai A; Ikegawa A; Wada T; Usami I; Maihara T; Komai T; Heike T; Nishida Y; Kobayashi K
    Int J Lab Hematol; 2022 Apr; 44(2):349-355. PubMed ID: 34761527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
    Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
    Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
    Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
    Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sensitive and inexpensive high-resolution melting-based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
    Camargo R; de Castro Moreira Dos Santos A; Cândido Guido B; Lemos Mendanha Cavalcante L; Silva Dias AC; Mendonça de Pontes R; Magalhães Furtado F; Feitosa Salviano C; Tiziani V; Martins Córdoba JC; Quezado Magalhães IM
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29866. PubMed ID: 35731576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
    Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
    Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
    Watanabe K
    Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The landscape of somatic mutations in Down syndrome-related myeloid disorders.
    Yoshida K; Toki T; Okuno Y; Kanezaki R; Shiraishi Y; Sato-Otsubo A; Sanada M; Park MJ; Terui K; Suzuki H; Kon A; Nagata Y; Sato Y; Wang R; Shiba N; Chiba K; Tanaka H; Hama A; Muramatsu H; Hasegawa D; Nakamura K; Kanegane H; Tsukamoto K; Adachi S; Kawakami K; Kato K; Nishimura R; Izraeli S; Hayashi Y; Miyano S; Kojima S; Ito E; Ogawa S
    Nat Genet; 2013 Nov; 45(11):1293-9. PubMed ID: 24056718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations.
    Nakashima MO; Shetty S; Chicka M; Flagg A; Eng C; Cotta CV
    Pediatr Blood Cancer; 2015 Feb; 62(2):353-355. PubMed ID: 25175265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
    Roy A; Roberts I; Vyas P
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation characterization in the GATA-1 gene in patients with Down's Syndrome diagnosed with transient abnormal myelopoiesis or acute megakaryoblastic leukemia.
    Mansini AP; Rubio PL; Rossi JG; Gallego MS; Medina A; Zubizarreta PA; Felice MS; Alonso CN
    Arch Argent Pediatr; 2013 Dec; 111(6):532-6. PubMed ID: 24196768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient abnormal myelopoiesis in non-Down syndrome neonate.
    Ohkawa T; Miyamoto S; Sugie M; Tomizawa D; Imai K; Nagasawa M; Morio T; Mizutani S; Takagi M
    Pediatr Int; 2015; 57(1):e14-7. PubMed ID: 25711269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete blood count differences in a cohort of Down syndrome neonates with transient abnormal myelopoiesis screened for GATA1 pathogenic variants.
    Orozco-Vela M; Corona-Rivera A; Cruz-Osorio RM; Mendoza-Maldonado L; Márquez-Mora A; Barba-Barba CC; Peña-Padilla C; Baldomero-López A; Bobadilla-Morales L; Corona-Rivera JR
    Am J Med Genet A; 2020 Sep; 182(9):2085-2093. PubMed ID: 32681702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
    Anoop P; Atra A
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia-related malignancies.
    Lalonde E; Rentas S; Wertheim G; Cao K; Surrey LF; Lin F; Zhao X; Obstfeld A; Aplenc R; Luo M; Li MM
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
    Kim IS; Park ES; Lim JY; Ki CS; Chi HS
    J Korean Med Sci; 2008 Dec; 23(6):1105-8. PubMed ID: 19119459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome.
    Toki T; Kanezaki R; Kobayashi E; Kaneko H; Suzuki M; Wang R; Terui K; Kanegane H; Maeda M; Endo M; Mizuochi T; Adachi S; Hayashi Y; Yamamoto M; Shimizu R; Ito E
    Blood; 2013 Apr; 121(16):3181-4. PubMed ID: 23440243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Druschel CM; Sandoval C
    Blood; 2007 Sep; 110(6):2128-31. PubMed ID: 17576817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.